HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].

AbstractPURPOSE:
We report our technique and also preliminary results in the cases with localized prostate cancer treated by the combination of high-dose rate Iridium-192 (HDR-Ir192) brachytherapy and external irradiation.
MATERIALS AND METHODS:
From June 1999 to August 2000, 17 patients were treated by the combination of HDR-Ir 192 and external beam. The mean age of patients was 72 years (range, 48-81 years). The clinical stage was B1 in 5, B2 in 7 and C (no cancer with seminal vesicle) in 5 cases. Of 10 patients without neoadjuvant hormonal therapy, the median initial pretreatment PSA was 15.3 ng/ml (6.93-222.32 ng/ml). The treatment was given by HDR-Ir 192 brachytherapy (6 Gy x 3 times/2 days) and external beam irradiation (40 or 45 Gy). The brachytherapy was given using TRUS guided percutaneously inserted temporary needles with a high dose rate remote afterloading control. Local control was evaluated by digital rectal examination. TRUS-guided biopsies and serum PSA evaluations. Follow-up ranged from 2 to 14 months, with a median of 8 months.
RESULTS:
In 4 (40.0%) of 10 patients without neoadjuvant hormonal therapy the level of serum PSA was decreased to less than 4.0 ng/ml within 3 months after the therapy. The effective grade in the biopsy specimens of 8 patients without neoadjuvant hormonal therapy was Grade Ob in 4, Grade 1 in 1, Grade 3 in 3 cases at 3 months after the therapy. No severe intra- or peri-operative complications occurred.
CONCLUSION:
The combined radiotherapy treatment is safe and effective for use in the patients with localized prostate cancer. However, more comprehensive studies involving long-term follow-up and great numbers of the cases with localized prostate cancer treated by the combination of HDR-Ir 192 brachytherapy and external irradiation will be necessary to determine whether this therapy contributes to better prognosis.
AuthorsK Kasahara, K Inoue, T Karashima, Y Inoue, S Kariya, T Inomata, S Yoshida, T Shuin
JournalNihon Hinyokika Gakkai zasshi. The japanese journal of urology (Nihon Hinyokika Gakkai Zasshi) Vol. 92 Issue 5 Pg. 572-8 (Jul 2001) ISSN: 0021-5287 [Print] Japan
PMID11517568 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Iridium Radioisotopes
Topics
  • Aged
  • Aged, 80 and over
  • Brachytherapy (methods)
  • Humans
  • Iridium Radioisotopes (therapeutic use)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prostatic Neoplasms (pathology, radiotherapy)
  • Radiotherapy Dosage

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: